 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ALG-1007 / Allegro Ophthalmics
Discussion (Free Paper Forum: Podium 2) - Sep 16, 2019 - Abstract #ESCRS2019ESCRS_733;
Although the study does not have a vehicle control, the results indicate that the active ingredient (not the vehicle) is effective in improving signs and symptoms of DED in a statistically significant manner when comparing the 0.125% dose vs the 0.6% dose. The drug was well-tolerated with no drug-related SAEs, blurring of vision nor ocular irritation.
- ALG-1007 / Allegro Ophthalmics
Safety and efficacy of a novel integrin inhibitor ALG-1007 topical ophthalmic solution for the treatment of dry eye disease (Free Paper Forum: Podium 2) - Sep 16, 2019 - Abstract #ESCRS2019ESCRS_732;
Although the study does not have a vehicle control, the results indicate that the active ingredient (not the vehicle) is effective in improving signs and symptoms of DED in a statistically significant manner when comparing the 0.125% dose vs the 0.6% dose. The drug was well-tolerated with no drug-related SAEs, blurring of vision nor ocular irritation.
- ALG-1007 / Allegro Ophthalmics
Safety and Efficacy of a Novel Integrin Inhibitor, ALG-1007 Topical Solution, for the Treatment of Dry Eye Disease (STATION 3 Moscone Center) - Sep 5, 2019 - Abstract #AAO2019AAO_2955;
- ALG-1007 / Allegro Ophthalmics
Safety and Efficacy of a Novel Integrin Inhibitor, ALG-1007 Topical Solution, for the Treatment of Dry Eye Disease (Moscone Center EPOSTER & VIDEO TERMINALS) - Sep 5, 2019 - Abstract #AAO2019AAO_2197;
A Phase 2 study has been initiated using higher doses. Results from the study will also be presented.